Agent-Based Learning Model for the Obesity Paradox in RCC

Overview

Journal Front Bioeng Biotechnol

Date 2021 May 17

PMID 33996779

Citations 3

Authors

Matteo Belenchia

Giacomo Rocchetti

Stefano Maestri

Alessia Cimadamore

Rodolfo Montironi

Matteo Santoni

Emanuela Merelli

Affiliations

Soon will be listed here.

Abstract

A recent study on the immunotherapy treatment of renal cell carcinoma reveals better outcomes in obese patients compared to lean subjects. This enigmatic contradiction has been explained, in the context of the debated obesity paradox, as the produced by the cell-cell interaction network on the tumor microenvironment during the immune response. To better understand this hypothesis, we provide a computational framework for the study of the tumor behavior. The starting model of the tumor, based on the cell-cell interaction network, has been described as a multiagent system, whose simulation generates the hypothesized effects on the tumor microenvironment. The medical needs in the immunotherapy design meet the capabilities of a multiagent simulator to reproduce the dynamics of the cell-cell interaction network, meaning a reaction to environmental changes introduced through the experimental data.

Citing Articles

Exploiting the Role of Features for Antigens-Antibodies Interaction Site Prediction.

Quadrini M, Ferrari C Methods Mol Biol. 2024; 2780:303-325.

PMID: 38987475 DOI: 10.1007/978-1-0716-3985-6_16.

Obesity, the Adipose Organ and Cancer in Humans: Association or Causation?.

Trevellin E, Bettini S, Pilatone A, Vettor R, Milan G Biomedicines. 2023; 11(5).

PMID: 37238992 PMC: 10215824. DOI: 10.3390/biomedicines11051319.

Agent-based models for detecting the driving forces of biomolecular interactions.

Maestri S, Merelli E, Pettini M Sci Rep. 2022; 12(1):1878.

PMID: 35115584 PMC: 8814177. DOI: 10.1038/s41598-021-04205-8.

References

Celada F, Seiden P . A computer model of cellular interactions in the immune system. Immunol Today. 1992; 13(2):56-62. DOI: 10.1016/0167-5699(92)90135-T. View

Gong C, Milberg O, Wang B, Vicini P, Narwal R, Roskos L . A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. J R Soc Interface. 2017; 14(134). PMC: 5636269. DOI: 10.1098/rsif.2017.0320. View

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

Santoni M, Cortellini A, Buti S . Unlocking the secret of the obesity paradox in renal tumours. Lancet Oncol. 2019; 21(2):194-196. DOI: 10.1016/S1470-2045(19)30783-1. View

Santoni M, Conti A, Porta C, Procopio G, Sternberg C, Basso U . Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2014; 193(1):41-7. DOI: 10.1016/j.juro.2014.07.011. View

Vlahopoulos S . Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. Cancer Biol Med. 2017; 14(3):254-270. PMC: 5570602. DOI: 10.20892/j.issn.2095-3941.2017.0029. View

Merelli E, Pettini M, Rasetti M . Topology driven modeling: the IS metaphor. Nat Comput. 2015; 14(3):421-430. PMC: 4541713. DOI: 10.1007/s11047-014-9436-7. View

Merelli E, Armano G, Cannata N, Corradini F, dInverno M, Doms A . Agents in bioinformatics, computational and systems biology. Brief Bioinform. 2006; 8(1):45-59. DOI: 10.1093/bib/bbl014. View

10.

Gedye C, Sirskyj D, Lobo N, Meens J, Hyatt E, Robinette M . Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. Sci Rep. 2016; 6:25220. PMC: 4848484. DOI: 10.1038/srep25220. View

11.

Kim H, Cantor H . CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014; 2(2):91-8. DOI: 10.1158/2326-6066.CIR-13-0216. View

12.

Dandekar R, Kingaonkar A, Dhabekar G . Role of macrophages in malignancy. Ann Maxillofac Surg. 2013; 1(2):150-4. PMC: 3591014. DOI: 10.4103/2231-0746.92782. View

13.

Mailliard R, Egawa S, Cai Q, Kalinska A, Bykovskaya S, Lotze M . Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med. 2002; 195(4):473-83. PMC: 2193623. DOI: 10.1084/jem.20011662. View

14.

Castoldi A, de Souza C, Camara N, Moraes-Vieira P . The Macrophage Switch in Obesity Development. Front Immunol. 2016; 6:637. PMC: 4700258. DOI: 10.3389/fimmu.2015.00637. View

15.

Chen Y, Li C, Xie H, Fan Y, Yang Z, Ma J . Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→︀AKT→︀GSK3β→︀AM signaling. Oncogene. 2017; 36(20):2879-2888. PMC: 5442425. DOI: 10.1038/onc.2016.442. View

16.

Baish J, Stylianopoulos T, Lanning R, Kamoun W, Fukumura D, Munn L . Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A. 2011; 108(5):1799-803. PMC: 3033252. DOI: 10.1073/pnas.1018154108. View

17.

Naylor C, Petri Jr W . Leptin Regulation of Immune Responses. Trends Mol Med. 2016; 22(2):88-98. DOI: 10.1016/j.molmed.2015.12.001. View

18.

Koucky V, Boucek J, Fialova A . Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review. Cancers (Basel). 2019; 11(4). PMC: 6520684. DOI: 10.3390/cancers11040470. View

19.

Davies P, Demetrius L, Tuszynski J . Cancer as a dynamical phase transition. Theor Biol Med Model. 2011; 8:30. PMC: 3177875. DOI: 10.1186/1742-4682-8-30. View

20.

Cosgrove J, Butler J, Alden K, Read M, Kumar V, Cucurull-Sanchez L . Agent-Based Modeling in Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol. 2016; 4(11):615-29. PMC: 4716580. DOI: 10.1002/psp4.12018. View